Abstracts tagged "Pulmonary Involvement"

Abstract Number: 826 • 2016 ACR/ARHP Annual Meeting
Exercise Echocardiography Predicts Future Development of Pulmonary Hypertension in a High-Risk Cohort of Scleroderma Patients
Kaitlin A. Quinn¹, Tunay Kuru², Stephanie Wappel³ and Virginia D. Steen¹, ¹Rheumatology, Georgetown University Medical Center, Washington, DC, ²Pulmonary, Georgetown University Medical Center, Washington, DC, ³Georgetown University Medical Center, Washington, DC
Background/Purpose: Pulmonary hypertension (PH) is the leading cause of scleroderma related deaths and is often detected late in the disease course. Early identification of patients…
Abstract Number: 835 • 2016 ACR/ARHP Annual Meeting
A Normal Pulmonary Diffusion Capacity Is Rare in Pulmonary Artery Hypertension in Systemic Sclerosis
Rebecca Overbury¹, Tracy M. Frech², Maureen Murtaugh³, Virginia D. Steen⁴ and PHAROS investigators, ¹Internal Medicine and Pediatrics, University of Utah, Salt Lake City, UT, ²Division of Rheumatology, University of Utah, Salt Lake City, UT, ³University of Utah, Salt Lake, UT, ⁴Rheumatology, Georgetown University Medical Center, Washington, DC
Background/Purpose: Methods: Results: > 70% (mean 78%) versus 191 patients (94.6%) who had a low DLCO <70% (mean 39%). There was no difference…
Abstract Number: 838 • 2016 ACR/ARHP Annual Meeting
Esophageal Dysmotility and Interstitial Lung Disease in Patients with Scleroderma: A Retrospective Study
Shweta Kishore¹, Santhanam Lakshminarayanan¹, Chia-Ling Kuo² and Ranadeep Mandhadi¹, ¹Division of Rheumatology, University of Connecticut, Farmington, CT, ²Department of Community Medicine and Health Care, University of Connecticut, Farmington, CT
Background/Purpose: Systemic sclerosis (SSc) is a connective tissue disease with pulmonary involvement seen in 75% of patients and esophageal involvement in 90% of the patients.…
Abstract Number: 972 • 2016 ACR/ARHP Annual Meeting
Outcome of the Scleroderma Population “at Risk” to Develop Pulmonary Hypertension in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Cohort Study
Vivien Hsu¹, Virginia D. Steen² and PHAROS Investigators, ¹Rheumatology, RWJ Med Schl Scleroderma Prog, New Brunswick, NJ, ²Rheumatology, Georgetown University Medical Center, Washington, DC
ABSTRACT: Background/Purpose: We investigated predictors of outcome, including mortality and cardiopulmonary hospitalizations in the Òat riskÓ group for pulmonary hypertension in PHAROS, a prospective longitudinal…
Abstract Number: 973 • 2016 ACR/ARHP Annual Meeting
Clinical Characterization of Patients with World Health Organization Group 2 Pulmonary Hypertension in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Cohort
Jessica K. Gordon¹, Jackie Szymonifka², Matthew R. Lammi³, Virginia D. Steen⁴ and PHAROS Investigators, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Epidemiology and Biostatistics, Hospital for Special Surgery, New York, NY, ³Louisiana State University Health Sciences Center, Pulmonary and Critical Medicine, New Orleans, LA, ⁴Rheumatology, Georgetown University Medical Center, Washington, DC
Background/Purpose: Pulmonary hypertension (PH) is a leading cause of death in patients (pts) with Systemic Sclerosis (SSc). The World Health Organization (WHO) classifies PH into…
Abstract Number: 109 • 2015 ACR/ARHP Annual Meeting
Association of HLA-G and Leukocyte Immunoglobulin-like Receptor A3 Polymorphisms with the Susceptibility to Pulmonary Hyterpention in Systemic Sclerosis
Yuki Hachiya¹, Aya Kawasaki¹, Takashi Matsushita², Hiroshi Furukawa¹, Shouhei Nagaoka³, Kota Shimada⁴, Shoji Sugii⁴, Keigo Setoguchi⁵, Akira Okamoto⁶, Noriyuki Chiba⁷, Eiichi Suematsu⁸, Masao Katayama⁹, Shunsei Hirohata¹⁰, Hajime Kono¹¹, Kiyoshi Migita¹², Takayuki Sumida¹³, Shigeto Tohma¹⁴, Minoru Hasegawa¹⁵, Manabu Fujimoto¹⁶, Shinichi Sato¹⁷, Kazuhiko Takehara¹⁸ and Naoyuki Tsuchiya¹⁹, ¹Molecular and Genetic Epidemiology Laboratory, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ²Department of Dermatology, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa city, Japan, ³Rheumatology, Yokohama Minami Kyosai Hospital, Yokohama, Japan, ⁴Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Fuchu, Japan, ⁵Department of Allergy and Immunological Diseases, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan, ⁶Department of Rheumatology,, Himeji Medical Center, National Hospital Organization, Himeji, Japan, ⁷Department of Rheumatology, Morioka National Hospital, NHO, Iwate, Japan, ⁸Department of Internal Medicine and Rheumatology, National Hospital Organization, Kyushu Medical Research Center, Fukuoka, Japan, ⁹Division of Rheumatology, Department of Internal Medicine, Nagoya Medical Center, National Hospital Organization, Nagoya City, Aichi, Japan, ¹⁰Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, Japan, ¹¹Department of Internal Medicine, Teikyo University, Tokyo, Japan, ¹²Department of Rheumatology and Clinical Research Center, Nagasaki Medical Center, Omura, Japan, ¹³Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ¹⁴Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan, ¹⁵Dermatology, Faculty of Medical Sciences, University of Fukui, Fukui, Japan, ¹⁶Department of Dermatology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ¹⁷Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan, ¹⁸Dermatology, Department of Dermatology, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa city, Japan, ¹⁹Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
Background/Purpose: Human leukocyte antigen-G (HLA-G) is a non-classical class I molecule expressed in the immune cells, the spleen, and the lungs, and plays a key…
Abstract Number: 203 • 2015 ACR/ARHP Annual Meeting
Rescue of Copa Syndrome Cellular Phenotype By Autophagy Modifying Drugs
Levi Watkin^1,2, Briana Burns^1,2, Timothy Vece³ and Jordan S. Orange^1,2, ¹Baylor College of Medicine, Houston, TX, ²Center for Human Immunobiology, Texas Children's Hospital, Houston, TX, ³Pulmonology, Texas Children's Hospital, Houston, TX
Background/Purpose: Autoimmunity is a diverse group of complex conditions that can include certain congenital genetic defects leading to loss of self-tolerance with subsequent imbalances of…
Abstract Number: 2374 • 2015 ACR/ARHP Annual Meeting
Pulmonary Arterial Hypertension in Patients with Anti-PM-Scl Antibody
Hiromichi Tamaki¹, Ruchi Yadav², James Bena³ and Soumya Chatterjee⁴, ¹Department of Rheumatic and Immunologic Diseases, Cleveland Clinic Foundation, Cleveland, OH, ²Diagnostic Radiology, Cleveland Clinic, Cleveland, OH, ³Department of Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, OH, ⁴Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: Pulmonary arterial hypertension (PAH) may be a disease manifestation of patients with anti-PM-Scl antibody (PM-Scl). In the 2014 ACR annual meeting we reported significantly…
Abstract Number: 2973 • 2015 ACR/ARHP Annual Meeting
Exercise Intolerance Evaluated By Invasive Cardiopulmonary Exercise Testing in Connective Tissue Disease: Beyond Pulmonary Hypertension
Rudolf Oliveira^1,2, David Systrom², Julie Tracy², Abbey Karin², Aaron Waxman², Paul Dellaripa³ and Paul Hoover³, ¹Medicine, Division of Respiratory Disease, Federal University Of São Paulo, São Paulo, Brazil, ²Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, MA, ³Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Exercise intolerance is common in patients with connective tissue disease (CTD) and may be related to pulmonary hypertension (PH). However, determining the exact etiology…
Abstract Number: 2990 • 2015 ACR/ARHP Annual Meeting
Assessment of NT-Pro BNP As a Potential Marker for Pulmonary Hypertension in Systemic Sclerosis: Data from a Large, Prospective and Unselected Patient Cohort
Anna-Maria Hoffmann-Vold^1,2, Oyvind Midtvedt¹, Torhild Garen³, May Brit Lund⁴, Arne Andreassen⁵ and Øyvind Molberg⁶, ¹Rheumatology, Oslo University Hospital, Oslo, Norway, ²Institute of clinical medicine, University of Oslo, Oslo, Norway, ³Rheumatology, Department of Rheumatology, Oslo University Hospital, Oslo, Norway, ⁴Respiratory Diseases, Oslo University Hospital, Oslo, Norway, ⁵Cardiology, Oslo University Hospital, Oslo, Norway, ⁶Department of Rheumatology, Institute of Clinical Medicine, Oslo University Hospital, Oslo, Norway
Background/Purpose: In Systemic Sclerosis (SSc), pulmonary arterial hypertension (PAH) is often diagnosed at an advanced stage. Serum levels of N-terminal pro-brain natriuretic peptide (NT-proBNP) are…
Abstract Number: 1696 • 2014 ACR/ARHP Annual Meeting
Left Atrial Area Measurement Is Useful for Evaluating Left Ventricular Diastolic Dysfunction Coexisting with Pulmonary Arterial Hypertension Associated with Systemic Sclerosis
Sumiaki Tanaka¹, Nobuhiro Sho², Tatsuo Nagai³, Yoshiyuki Arinuma² and Shunsei Hirohata¹, ¹Int Med/Rheumatol & Infec Dis, Kitasato University School of Medicine, Sagamihara, Japan, ²Kitasato University School of Medicine, Sagamihara, Japan, ³Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Sagamihara, Japan
Background/Purpose: Pulmonary arterial hypertension (PAH) is a crucial organ involvement affecting survival of patients with connective tissue disease (CTDs), such as systemic sclerosis (SSc), systemic…
Abstract Number: 1692 • 2014 ACR/ARHP Annual Meeting
The Additive Value of Nailfold Videocapillaroscopy Patterns to Disease-Specific Autoantibodies in Discrimination of Patients with Systemic Sclerosis at Risk for Severe Organ Involvement
I.M. Markusse¹, J. Meijs², B. de Boer², A. a. Schouffoer¹, N. Ajmone Marsan³, L. J. M. Kroft⁴, M. K. Ninaber⁵, T. W. J. Huizinga² and J.K. de Vries-Bouwstra⁶, ¹Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Cardiology, Leiden University Medical Center, Leiden, Netherlands, ⁴Deparment of Radiology, Leiden University Medical Center, Leiden, Netherlands, ⁵Pulmonology, Leiden University Medical Center, Leiden, Netherlands, ⁶Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Severe nailfold videocapillaroscopy (NVC) patterns in patients with systemic sclerosis (SSc) are associated with a high risk of organ involvement. SSc-specific autoantibodies seem to…
Abstract Number: 1441 • 2014 ACR/ARHP Annual Meeting
Accelerated Aging in DMARD and Treatment Naive Early Rheumatoid Arthritis Patients Measured By a Stem Cell Assay Is Associated with Increased LDL and Is Linked to Impaired Cardiopulmonary Function
Torkell Ellingsen^1,2,3, Henriette Jørgensen⁴, Dino Demirovic⁴, Lone Deibjerg⁵, Frank Andersen⁵, Agnete Hedemann-Andersen⁵, Brian Bridal Løgstrup^5,6 and Suresh Rattan⁴, ¹Diagnostic Centre Region, Hospital Silkeborg Denmark, Odense, Denmark, ²The Danish National Registry DANBIO, Odense, Denmark, ³Department of Rheumatology, Odense University Hospital, Denmark, Odense, Denmark, ⁴Laboratory of Cellular Ageing, Institute of Molecular Biology and Genetics, Århus University, Århus, Denmark, ⁵Diagnostic Centre Region, Hospital Silkeborg Denmark, Silkeborg, Denmark, ⁶Cardiology, Skejby Hospital, Århus Universityhosital, Århus, Denmark
Background/Purpose: The cardiovascular comorbidity seen in early treatment naive rheumatoid arthritis (RA) can be considered as an aspect of ´´accelerated aging``. Methods: We investigated cell…
Abstract Number: 724 • 2014 ACR/ARHP Annual Meeting
Moderate Decline in Forced Vital Capacity is Associated with a Poor Outcome in Systemic Sclerosis Patients
Anna-Maria Hoffmann-Vold¹, Oyvind Midtvedt², Torhild Garen³, May Brit Lund⁴, T. Mogens Aalokken⁵, Jan Tore Gran² and Oyvind Molberg⁶, ¹Department of Rheumatology, Department of Rheumatology, Oslo University Hospital Rikshospitalet, Oslo, Norway, ²Rheumatology, Oslo University Hospital, Oslo, Norway, ³Department of Rheumatology, Oslo University Hospital Rikshospitalet, Oslo, Norway, ⁴Department of Respiratory Medicine, Oslo University Hospital Rikshopitalet, Oslo, Norway, ⁵Department of Radiology, Oslo University Hospital Rikshospitalet, Oslo, Norway, ⁶Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway
Background/Purpose: Interstitial lung disease (ILD) is a common manifestation in systemic sclerosis (SSc) and the leading cause of morbidity and mortality. Serial pulmonary function tests…
Abstract Number: 2751 • 2014 ACR/ARHP Annual Meeting
18F-FDG PET/CT in Vascular Disease Due to Behçet’s Syndrome
Emire Seyahi¹, Metin Hallac², Betul Vatankulu³, Serdal Ugurlu¹, Melike Melikoglu⁴, Sebahattin Yurdakul¹ and Hasan Yazici⁴, ¹Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ²Department of Nuclear Medicine, Cerrahpasa Medical Faculty, University Of Istanbul, Istanbul, Turkey, ³Department of Nuclear Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ⁴Istanbul University, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey
Background/Purpose 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT is considered as a useful tool in assessing active vascular inflammation in large vessel vasculitis. Lower extremity vein…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].